Not recruiting
Investigational
Phase 3 Study of Zigakibart (BION-1301) in Adults with IgA Nephropathy
Investigational
- Substances:Zigakibart
Countries:
Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Zigakibart
- Sponsor:Novartis Pharma AG
Back to ItalyClinical trials in Bari – page 20
401 clinical trials in Bari, Italy across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in ItalyStudi-Clinici.it(opens in a new tab)Bari at a glance
401
clinical trials
- Research sites3
Not recruiting
Choroidal neovascularisation
Not recruitingFaricimab for Choroidal Neovascularization Secondary to Pathologic Myopia in Patients with Pathologic Myopia
Registered drugNo placebo
Faricimab for Choroidal Neovascularization Secondary to Pathologic Myopia in Patients with Pathologic Myopia
Registered drugNo placebo
- Disease:Choroidal neovascularisation
- Substances:FaricimabRanibizumab
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Faricimab
- Sponsor:F. Hoffmann-La Roche AG
Not recruiting
Small cell lung cancer extensive stage
Not recruitingStudy of tarlatamab and durvalumab compared to durvalumab alone for patients with extensive stage small cell lung cancer
Registered drugNo placebo
Study of tarlatamab and durvalumab compared to durvalumab alone for patients with extensive stage small cell lung cancer
Registered drugNo placebo
- Disease:Small cell lung cancer extensive stage
- Substances:ArgipressinCarboplatin+14
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Argipressin
- Sponsor:Amgen Inc.
Not recruiting
Relapsing multiple sclerosis
Not recruitingPhase III Study of the Efficacy and Safety of Fenebrutinib Compared with Teriflunomide in Adult Patients with Relapsing Multiple Sclerosis
Registered drug
Phase III Study of the Efficacy and Safety of Fenebrutinib Compared with Teriflunomide in Adult Patients with Relapsing Multiple Sclerosis
Registered drug
- Disease:Relapsing multiple sclerosis
- Substances:FenebrutinibTeriflunomide
Countries:Italy
Italy- Participants:18–64 years
- Substances:Fenebrutinib
- Sponsor:F. Hoffmann-La Roche AG
Not recruiting
Chronic obstructive pulmonary disease
Not recruitingA study testing tozorakimab for long-term treatment of chronic obstructive pulmonary disease in former smokers with repeated flare-ups
Registered drug
A study testing tozorakimab for long-term treatment of chronic obstructive pulmonary disease in former smokers with repeated flare-ups
Registered drug
- Disease:Chronic obstructive pulmonary disease
- Substances:SalbutamolTozorakimab
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Salbutamol
- Sponsor:AstraZeneca AB
Not recruiting
Dermatomyositis
Not recruitingA study testing brepocitinib compared to placebo for adults with dermatomyositis to see if it works and is safe
Investigational
A study testing brepocitinib compared to placebo for adults with dermatomyositis to see if it works and is safe
Investigational
- Disease:Dermatomyositis
- Substances:Brepocitinib Tosilate
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Brepocitinib Tosilate
- Sponsor:Priovant Therapeutics Inc.
Not recruiting
Malignant melanoma stage IV+1
Not recruitingStudy of BNT111 and cemiplimab in patients with advanced melanoma who have not responded to other therapies
Registered drugNo placebo
Study of BNT111 and cemiplimab in patients with advanced melanoma who have not responded to other therapies
Registered drugNo placebo
- Disease:Malignant melanoma stage IVMalignant melanoma stage III
- Substances:CemiplimabEnomimeran+3
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Cemiplimab
- Sponsor:BioNTech SE
Not recruiting
Endocrine ophthalmopathy
Not recruitingStudy of VRDN-001 compared to placebo to evaluate safety and effectiveness in adults with chronic thyroid eye disease
Registered drug
Study of VRDN-001 compared to placebo to evaluate safety and effectiveness in adults with chronic thyroid eye disease
Registered drug
- Disease:Endocrine ophthalmopathy
- Substances:Sodium ChlorideVRDN-001
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Sodium Chloride
- Sponsor:Viridian Therapeutics Inc.
Not recruiting
Migraine
Not recruitingStudy of rimegepant for preventing chronic migraine in adolescents aged 12 to 17 years
Registered drug
Study of rimegepant for preventing chronic migraine in adolescents aged 12 to 17 years
Registered drug
- Disease:Migraine
- Substances:Rimegepant sulfate
Countries:Italy
Italy- Participants:0–17 years
- Substances:Rimegepant sulfate
- Sponsor:Pfizer Inc.
Not recruiting
Chronic obstructive pulmonary disease
Not recruitingStudy of tozorakimab to reduce exacerbations in former smokers with chronic obstructive pulmonary disease (COPD)
Registered drug
Study of tozorakimab to reduce exacerbations in former smokers with chronic obstructive pulmonary disease (COPD)
Registered drug
- Disease:Chronic obstructive pulmonary disease
- Substances:Salbutamol SulfateTozorakimab
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Salbutamol Sulfate
- Sponsor:AstraZeneca AB
Not recruiting
Small cell lung cancer extensive stage
Not recruitingStudy of tarlatamab with durvalumab, carboplatin and etoposide versus standard treatment in patients with previously untreated extensive stage small cell lung cancer
Registered drugNo placebo
Study of tarlatamab with durvalumab, carboplatin and etoposide versus standard treatment in patients with previously untreated extensive stage small cell lung cancer
Registered drugNo placebo
- Disease:Small cell lung cancer extensive stage
- Substances:CarboplatinDurvalumab+5
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Carboplatin
- Sponsor:Amgen Inc.
Not recruiting
Congenital cystic kidney disease
Not recruitingStudy of ABBV-CLS-628 to evaluate safety and effectiveness in adults with Autosomal Dominant Polycystic Kidney Disease
Investigational
Study of ABBV-CLS-628 to evaluate safety and effectiveness in adults with Autosomal Dominant Polycystic Kidney Disease
Investigational
- Disease:Congenital cystic kidney disease
- Substances:ABBV-CLS-628
Countries:Italy
Italy- Participants:18–64 years
- Substances:ABBV-CLS-628
- Sponsor:Calico Life Sciences LLC
Other cities in Italy
The busiest research cities in the country
Clinical research in Bari
What the registry says about research in the country
01 Oncology Research
Studies focusing on innovative treatments for various cancers, including metastatic colorectal cancer, non-small cell lung cancer, and malignant pleural mesothelioma. Research evaluates new therapeutic approaches and drug combinations.
- Colorectal Cancer Treatment Studies
- Lung Cancer Therapies
- Mesothelioma Management
Advanced clinical trials testing targeted therapies and immunotherapy approaches.
02 Infectious Disease Prevention
Investigations into vaccines and preventive treatments for various infectious conditions, particularly respiratory syncytial virus (RSV) and influenza. Studies include both pediatric and adult populations.
- Vaccine Development
- RSV Prevention
- Influenza Protection
Focus on immunogenicity and safety in different age groups.
03 Hematologic Disorders
Research examining treatments for blood-related conditions, including chronic myeloid leukemia and acute myeloid leukemia. Studies evaluate novel therapeutic approaches and drug combinations.
- Leukemia Treatments
- Targeted Therapies
- Clinical Outcomes
Emphasis on personalized treatment approaches and molecular targeting.